Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study
暂无分享,去创建一个
Jennifer D. Brooks | D. Duggan | E. John | D. Stram | L. Bernstein | J. Knight | M. Robson | R. Shore | P. Concannon | D. Thomas | J. Brooks | J. Bernstein | A. Reiner | R. Haile | X. Liang | K. Malone | C. Lynch | Susan A. Smith | L. Mellemkjaer | Duncan C. Thomas | Meghan Woods
[1] Jane E. Carpenter,et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS , 2016, Journal of Medical Genetics.
[2] Jane E. Carpenter,et al. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.
[3] Patrick Neven,et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer , 2015 .
[4] M. Pollán,et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.
[5] R. Weigel,et al. Review of risk factors for the development of contralateral breast cancer. , 2013, American journal of surgery.
[6] Karen R. Sepucha,et al. Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer , 2013, Annals of Internal Medicine.
[7] Jaana M. Hartikainen,et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.
[8] Jennifer D. Brooks,et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Cross,et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Begg,et al. Rare germline mutations in PALB2 and breast cancer risk: A population‐based study , 2012, Human mutation.
[11] D. Duggan,et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study , 2011, Breast Cancer Research.
[12] P. Oefner,et al. Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.
[13] A. Stewart,et al. Trends in Contralateral Prophylactic Mastectomy for Unilateral Cancer: A Report From the National Cancer Data Base, 1998–2007 , 2010, Annals of Surgical Oncology.
[14] Hoda Anton-Culver,et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Begg,et al. Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study , 2010, Cancer Causes & Control.
[16] Alun Thomas,et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.
[17] P. Donnelly,et al. A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.
[18] A. Børresen-Dale,et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. , 2008, Cancer research.
[19] A. Børresen-Dale,et al. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study , 2008, British Journal of Cancer.
[20] T. Tuttle,et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[22] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[23] Bryan Langholz,et al. Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study , 2004, Breast Cancer Research.
[24] A. Børresen-Dale,et al. Designing and implementing quality control for multi‐center screening of mutations in the ATM gene among women with breast cancer , 2003, Human mutation.
[25] W. Thompson,et al. Epidemiology of contralateral breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[26] Jane E. Carpenter,et al. PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS , 2016 .
[27] C. Melissa,et al. CHEK2 and ATM rare variants and cancer risk: data from COGS. , 2016 .
[28] A. Børresen-Dale,et al. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. , 2010, Journal of the National Cancer Institute.